# US 2025/0154607 A1 · Isothermal amplification of pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154607 A1
- Document ID: US20250154607A1
- Status: Published application
- Kind: A1
- Application number: 18/548,972
- Filed: 2022-03-18
- Published: 2025-05-15
- Earliest claimed: 2021-03-19
- Assignees: Becton, Dickinson and Company
- Applicants: Becton, Dickinson and Company
- Inventors: Honghua ZHANG; Andrew P. MILLER; Brion MERMER; Li-Chun TSAI
- Web page: https://patentgrep.com/patent/US20250154607A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/689: for bacteria
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/701: {Specific hybridization probes}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein include methods, compositions, and kits for use in detecting a target nucleic acid sequence in a sample. The method can comprise the use of a lysis buffer comprising a lytic agent and/or a reducing agent for treating a sample and detecting the presence of a target nucleic acid sequence. In some embodiments, the method comprises contacting a reagent composition comprising amplification agents and one or more protectants (e.g., cyclodextrin compounds) capable of sequestering lytic agents with the treated sample to generate an amplification reaction mixture, for example under isothermal conditions, for detecting.

## Claims

### Claim 1

A method for detecting a target nucleic acid sequence in a sample, comprising:
(a) contacting a sample comprising biological entities with a lysis buffer to generate a treated sample, wherein the lysis buffer comprises one or more lytic agents capable of lysing the biological entities to release sample nucleic acids comprised therein, and wherein the sample nucleic acids are suspected of comprising a target nucleic acid sequence;
(b) contacting a reagent composition with the treated sample to generate an amplification reaction mixture, wherein the reagent composition comprises one or more protectants and one or more amplification reagents;
(c) amplifying the target nucleic acid sequence in the amplification reaction mixture, thereby generating a nucleic acid amplification product; and
(d) detecting the nucleic acid amplification product, wherein the detecting is performed in less than about 20 minutes from the time the reagent composition is contacted with the treated sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lysis buffer and/or reagent composition comprises one or more reducing agents.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more amplification reagents comprise a reverse transcriptase and/or an enzyme having a hyperthermophile polymerase activity.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the reagent composition is lyophilized, heat-dried, and/or comprises one or more additives.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the one or more protectants comprises a cyclodextrin compound of formula (I):
or a salt, ester, solvate or hydrate thereof, wherein,
each R is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted; or —C(O)ORB, —OC(O)RB, —C(O)RB, or —C(O)NRARB;
each R1 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halogen, hydroxy, amino, —CN, —CF3, —N3, —NO2, —ORB, —SRB, —SORB, —SO2RB, —N(RB)S(O2) —RB, —N(RB) S(O2)NRARB, —NRARB, —C(O)ORB, —OC(O)RB, —C(O)RB, —C(O)NRARB, or —N(RB)C(O)RB; each of which is optionally substituted;
each RA is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
each RB is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
each m is independently 0, 1, 2, 3, 4, or 5.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the one or more lytic reagents comprise:
about 0.001% (w/v) to about 1.0 (w/v) of the treated sample.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein amplifying the target nucleic acid sequence comprises:
amplifying a target nucleic acid sequence comprising a first strand and a second strand complementary to each other in an isothermal amplification condition, wherein the amplifying comprises contacting a nucleic acid comprising the target nucleic acid sequence with:
i) a first primer and a second primer, wherein the first primer is capable of hybridizing to a sequence of the first strand of the target nucleic acid sequence, and the second primer is capable of hybridizing to a sequence of the second strand of the target nucleic acid sequence; and
ii) an enzyme having a hyperthermophile polymerase activity, thereby generating a nucleic acid amplification product, wherein the nucleic acid amplification product comprises:
(1) the sequence of the first primer, and the reverse complement thereof,
(2) the sequence of the second primer, and the reverse complement thereof, and
(3) a spacer sequence flanked by (1) the sequence of the first primer and the reverse complement thereof and (2) the sequence of the second primer and the reverse complement thereof, wherein the spacer sequence is 1 to 10 bases long.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein amplifying the target nucleic acid sequence comprises:
(c1) contacting sample ribonucleic acids with a reverse transcriptase and/or a reverse transcription primer to generate a cDNA;
(c2) contacting the cDNA with an enzyme having a hyperthermophile polymerase activity to generate a double-stranded DNA (dsDNA), wherein the dsDNA comprises a target nucleic acid sequence, and wherein the target nucleic acid sequence comprises a first strand and a second strand complementary to each other;
(c3) amplifying the target nucleic acid sequence under an isothermal amplification condition, wherein the amplifying comprises contacting the dsDNA with:
(i) a first primer and a second primer, wherein the first primer is capable of hybridizing to a sequence of the first strand of the target nucleic acid sequence, and the second primer is capable of hybridizing to a sequence of the second strand of the target nucleic acid sequence; and
(ii) the enzyme having a hyperthermophile polymerase activity, thereby generating a nucleic acid amplification product, wherein the nucleic acid amplification product comprises:
(1) the sequence of the first primer, and the reverse complement thereof,
(2) the sequence of the second primer, and the reverse complement thereof, and
(3) a spacer sequence flanked by (1) the sequence of the first primer and the reverse complement thereof and (2) the sequence of the second primer and the reverse complement thereof, wherein the spacer sequence is 1 to 10 bases long.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the enzyme having a hyperthermophile polymerase activity has an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein amplifying the target nucleic acid sequence is performed at a constant temperature of about 55° C. to about 75° C., or at a constant temperature of about 65° C.

### Claim 26 (depends on 21)

The method of claim 21, wherein:
the first primer, the second primer, and/or the reverse transcription primer is about 8 to 17 bases long;
the nucleic acid amplification product is about 20 to 40 bases long; and/or
the spacer sequence comprises a portion of the target nucleic acid sequence.

### Claim 27 (depends on 1)

The method of claim 1, further comprising contacting the nucleic acid amplification product with a signal-generating oligonucleotide capable of hybridizing to the amplification product, wherein the signal-generating oligonucleotide comprises a fluorophore, a quencher, or both.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 2)

The method of claim 2, wherein the sample comprises a plurality of nucleases, wherein the nucleases comprise ribonucleases and/or deoxyribonucleases, and wherein:
the one or more lytic agents are capable of denaturing the ribonucleases to generate denatured ribonucleases, wherein the one or more reducing agents are capable of reducing the ribonucleases to generate reduced ribonucleases, and wherein the one or more reducing agents and the one or more lytic agents are capable of generating reduced-denatured ribonucleases; and/or
the one or more lytic agents are capable of denaturing the deoxyribonucleases to generate denatured deoxyribonucleases, wherein the one or more reducing agents are capable of reducing the deoxyribonucleases to generate reduced deoxyribonucleases, and wherein the one or more reducing agents and the one or more lytic agents are capable of generating reduced-denatured deoxyribonucleases.

### Claim 35 (depends on 34)

The method of claim 34, wherein:
denatured ribonucleases and/or reduced-denatured ribonucleases are capable of renaturing upon passage of time and/or upon reduced physical interaction with the one or more lytic agents, thereby generating renatured ribonucleases; and/or
denatured deoxyribonucleases and/or reduced-denatured deoxyribonucleases are capable of renaturing upon passage of time and/or upon reduced physical interaction with the one or more lytic agents, thereby generating renatured deoxyribonucleases.

### Claim 36 (depends on 34)

The method of claim 34, wherein denatured deoxyribonucleases, reduced deoxyribonucleases, reduced-denatured deoxyribonucleases, denatured ribonucleases, reduced ribonucleases, and/or reduced-denatured ribonucleases are enzymatically inactive, and wherein renatured ribonucleases and/or renatured deoxyribonucleases are enzymatically active.

### Claim 37 (depends on 34)

The method of claim 34, wherein:
reduced-denatured ribonucleases renature at least about 1.1-fold more slowly than denatured ribonucleases; and/or
reduced-denatured deoxyribonucleases renature at least about 1.1-fold more slowly than denatured deoxyribonucleases.

### Claim 38 (depends on 1)

The method of claim 1, wherein:
about 1.1-fold more sample ribonucleic acids are employed by the reverse transcriptase as template to generate cDNA as compared to a comparable method wherein the lysis buffer does not comprise one or more reducing agents; and/or
about 1.1-fold more sample deoxyribonucleic acids are employed by enzyme having a hyperthermophile polymerase activity as template to generate a nucleic acid amplification product to a comparable method wherein the lysis buffer does not comprise one or more reducing agents.

### Claim 39 (depends on 1)

The method of claim 1, wherein the amplification reaction mixture comprises an at least 1.1-fold lower nuclease activity ten minutes after step (b) and/or step (c) as compared to a comparable method wherein the lysis buffer does not comprise one or more reducing agents.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

A kit for detecting a target nucleic acid sequence in a sample, the kit comprising:
(a) a lysis buffer comprising one or more lytic agents capable of lysing biological entities to release sample nucleic acids comprised therein, wherein the sample nucleic acids are suspected of comprising a target nucleic acid sequence; and
(b) a reagent composition comprising one or more protectants and one or more amplification reagents comprising one or more components for amplifying the target nucleic acid sequence under isothermal amplification conditions, wherein said one or more components for amplifying comprise:
(i) a first primer and a second primer, wherein the first primer is capable of hybridizing to a sequence of a first strand of the target nucleic acid sequence, and the second primer is capable of hybridizing to a sequence of a second strand of the target nucleic acid sequence; and
(ii) an enzyme having a hyperthermophile polymerase activity capable of generating a nucleic acid amplification product.

### Claim 48 (depends on 47)

The kit of claim 47, wherein the lysis buffer and/or reagent composition comprises one or more reducing agents.

### Claim at position 49

49-60. (canceled)
